← Search & browse all drugs

butylscopolamine and analgesics

A03DB04

Forms & Strengths

Tablet: Butylscopolamine bromide 10 mg + Paracetamol 500 mg
Suppository: Butylscopolamine bromide 10 mg + Paracetamol 500 mg
Injection: Butylscopolamine bromide 20 mg + Analgesic combination per ampoule

Adult Dosing

Oral: 1-2 tablets 3-4 times daily; maximum 6 tablets daily
Rectal: 1 suppository 3-4 times daily
Parenteral: 20 mg (1 ampoule) IM or slow IV, may repeat after 30 minutes if needed

Pediatric Dosing

Children < 6 years: Not recommended or restricted to specialized formulations per weight
Children 6-12 years: Half the adult dose or as directed by a physician

Indications

Acute spasms of the gastrointestinal tract (e.g., biliary colic, renal colic)
Spasmodic dysmenorrhea
Visceral pain associated with smooth muscle spasm

Mechanism of Action

Butylscopolamine acts as a peripheral anticholinergic/antispasmodic agent, blocking muscarinic receptors on smooth muscle
Analgesic component (e.g., paracetamol) inhibits prostaglandin synthesis in the CNS and periphery to provide pain relief

Contraindications

Hypersensitivity to butylscopolamine, paracetamol, or anticholinergics
Myasthenia gravis
Megacolon
Narrow-angle glaucoma
Prostatic hypertrophy with urinary retention
Tachycardia

Adverse Reactions

Xerostomia (dry mouth)
Visual accommodation disturbances
Tachycardia
Constipation
Urinary retention
Hepatotoxicity (associated with paracetamol overdose)

Drug Interactions

Enhancement of anticholinergic effects with tricyclic antidepressants, antihistamines, and amantadine
Antagonism of gastrointestinal motility effects with prokinetic agents (e.g., metoclopramide)
Increased risk of paracetamol hepatotoxicity with chronic alcohol use or enzyme inducers

Curated Content: Needs Vetting Before Put to Clinical Use